ERBB2 and breast cancer: Hamy et al. [25], in a series of 716 breast cancers treated with NAC, showed that high post-NAC TIL levels were associated with aggressive tumor characteristics and with impaired EFS in HER2-positive breast cancers but not in luminal tumors or TNBC.